Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid

Biochemical Pharmacology

Volumn 55, Issue 5, 1998, Pages 635-648

  Kruczynski, Anna ^a   Barret, Jean Marc ^a   Etiévant, Chantal ^a   Colpaert, Francis ^a   Fahy, Jacques ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

In vitro cytotoxicity; Mitotic arrest; Tubulin assembly; Tubulin binding; Vinca alkaloids; Vinflunine

Indexed keywords

ANTIMITOTIC AGENT; NAVELBINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA L 1210; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELLS, CULTURED; GUANOSINE TRIPHOSPHATE; HYDROLYSIS; IODOACETAMIDE; LEUKEMIA L1210; MICE; MITOSIS; PROTEIN BINDING; RATS; TUBULIN; TUMOR CELLS, CULTURED; VINBLASTINE; VINCRISTINE;

EID: 0032031453     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00505-4     Document Type: Article

References (46)

1. 1. Donehower RC and Rowinsky EK, Anticancer drugs derived from plants. In: Cancer. Principles & Practice of Oncology. (Eds. DeVita VT, Hellman S and Rosenberg SA), pp. 409-417. J. B. Lippincott Company, Philadelphia, 1993.
2. 2. Noble RL, Beer CT and Cutts JH, Further biological activities of vincaleukoblastine - an alkaloid isolated from Vinca rosea (L.). Biochem Pharmacol 1: 347-348, 1958.
3. 3. Johnson IS, Wright HF and Svoboda GH, Experimental basis for clinical evaluation of anti-tumor principles derived from Vinca rosea Linn. J Lab Clin Med 54: 830, 1959.
4. 4. Svoboda GH, Alkaloids of Vinca rosea Linn. IX. Extraction and characterisation of leurosidine and leucocristine. Lloydia 24: 173-178, 1961.
5. 5. Barnett CJ, Cullinan GJ, Gerzon K, Hoying RC, Jones WE, Newlon WM, Poore GA, Robinson RL, Sweeney MJ, Todd GC, Dyke RW and Nelson RL, Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J Med Chem 21: 88-96, 1978.
6. 6. Johnson IS, Amstrong JG, Gorman M and Burnett JP, The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 23: 1390-1427, 1963.
7. 7. Van Tellingen O, Sips JHM, Beijnen JH, Bult A and Nooijen WJ, Pharmacology, bio-analysis and pharmacokinetics of the Vinca alkaloids and semi-synthetic derivatives (review). Anticancer Res 12: 1699-1716, 1992.
8. 8. Cersosimo RJ, Bromer R, Licciardello JTW and Ki Hong W, Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new Vinca alkaloid. Pharmacotherapy 3: 259-274, 1983.
9. 9. Goa KL and Faulds D, Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5: 200-234, 1994.
10. 10. Palmer CG, Livengood D, Warren AK, Simpson PJ and Johnson IS, The action of vincaleukoblastine on mitosis in vitro. Exp Cell Res 20: 198-265, 1960.
11. 11. Cutts JH, The effect of vincaleukoblastine on dividing cells in vivo. Cancer Res 21: 168-172, 1961.
12. 12. George P, Journey LJ and Goldstein MN, Effects of vincristine on the fine structure of HeLa cells during mitosis. J Natl Cancer Inst 35: 355-375, 1965.
13. 13. Jordan MA and Wilson L, Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29: 2730-2739, 1990.
14. 14. Na GC and Timasheff SN, In vitro vinblastine-induced tubulin paracrystals. J Mol Biol 187: 61-73, 1982.
15. 15. Singer WD and Himes RH, Cellular uptake and tubulin binding properties of four Vinca alkaloids. Biochem Pharmacol 43: 545-551, 1992.
16. 16. Lobert S, Vulevic B and Correia JJ, Interaction of Vinca alkaloids with tubulin: a comparison of vinblastine, vincristine and vinorelbine. Biochemistry 35: 6806-6814, 1996.
17. 17. Lafon C, Guerrin M, Barboule N, Mathieu C, Royer I, Monsarrat B, Wright M and Valette A, Inhibition of cell cycle progression and induction of apoptosis in NIH-OVCAR-3 ovarian adenocarcinoma cells. Anti-Cancer Drugs 7: 67-74, 1996.
18. 18. Fahy J, Duflos A, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP and Zunino F, Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119: 8576-8577, 1997.
19. 19. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J and Hill BT, In vivo antitumour activity of F 12158, a novel fluorinated Vinca alkaloid. In: Proc Am Assoc Cancer Res, San Diego, CA, 12-16 April 1997, 38: 224, 1997.
20. 20. Mosman T, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65: 55-63, 1983.
21. 21. Vindelov LL, Christensen IJ and Nissen NI, A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
22. 22. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T, Nagata H and Andoh TJ, Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 126: 1341-1351, 1994.
23. 23. Smith CD, Zhang X, Mooberry SL, Patterson GML and Moore RE, Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54: 3779-3784, 1994.
24. 24. Shelansky ML, Gaskin F and Cantor CR, Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci USA 70: 765-768, 1973.
25. 25. David-Pfeuty T, Simon C and Pantaloni D, Effects of antimitotic drugs on tubulin GTPase activity and self-assembly. J Biol Chem 254: 11696-11702, 1979.
26. 26. Lowry OH, Rosenbrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
27. 27. Gaskin F and Cantor CR, Turbidimetrie studies of the in vitro assembly and disassembly of porcine neurotubules. J Mol Biol 89: 737-758, 1974.
28. 28. Bai R, Pettit GR and Hamel E, Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Biochem Pharmacol 39: 1941-1949, 1990.
29. 29. Sackett DL and Varma JK, Molecular mechanism of colchicine action: induced local unfolding of β-tubulin. Biochemistry 32: 13560-13565, 1993.
30. 30. Hamel E and Lin C, Glutamate-induced polymerisation of tubulin: Characteristics of the reaction and application of the Large-Scale purification of tubulin. Arch Biochem Biophys 209: 29-40, 1981.
31. 31. Luduena RF and Roach MC, Interaction of tubulin with drugs and alkylating agents. 2. Effects of colchicine, podophyllotoxin, and vinblastine on the alkylation of tubulin. Biochemistry 20: 4444-4450, 1981.
32. 32. Hill BT and Whelan RDH, Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cells. J Natl Cancer Inst 67: 437-443, 1981.
33. 33. Pauwels O, Kiss R, Pasteels J and Atassi G, Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents. J Pharm Pharmacol 47: 870-875, 1995.
34. 34. Hamel E, Interaction of tubulin with small ligands. In: Microtubule Proteins (Eds. Avila J), pp. 89-191. CRC Press Inc., Boca Raton, Florida, 1990.
35. 35. Sackett DL, Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents. Biochemistry 34: 7010-7019, 1995.
36. 36. Bruce WR, Meeker BE and Valeriote FA, Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233-245, 1966.
37. 37. Hill BT, Whelan RDH, Shellard SA, McClean S and Hosking LK, Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182, 1994.
38. 38. Madoc-Jones H and Mauro F, Interphase action of vinblastine and vincristine: differences in their lethal actions through the mitotic cycle of cultured mammalian cells. J Cell Physiol 72: 185-196, 1968.
39. 39. Na GC and Timasheff SN, Stochiometry of the vinblastine-induced self-association of calf brain tubulin. Biochemistry 19: 1347-1354, 1980.
40. 40. De Arruda M, Cocchiaro CA, Nelson CM, Grinell CM, Janssen B and Haupt A, LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 55: 3085-3092, 1995.
41. 41. Walker D, Panda D, De Arruda M, Barlozzari T and Jordan MA, Inhibition of microtubule instability by LU103793 (NSC D-669356). In: Proc Am Assoc Cancer Res, Washington, DC, 20-24 April 1996, 37: 440, 1996.
42. 42. Owellen RJ, Owens AH and Donigian DW, The binding of vincristine, vinblastine, and colchicine to tubulin. Biochem Biophys Res Commun 47: 685-691, 1972.
43. 43. Prakash V and Timasheff SN, The interaction of vincristine with calf brain tubulin. J Biol Chem 258: 1689-1697, 1983.
44. 44. Jordan MA, Himes RH and Wilson L, Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 45: 2741-2747, 1985.
45. 45. Jordan MA, Thrower D and Wilson L, Mechanism of cell proliferation by Vinca alkaloids. Cancer Res 51: 2212-2222, 1991.
46. 46. Johnson SA, Harper P, Hortobagyi GN and Pouillart P, Vinorelbine: an overview. Cancer Treat Rev 22: 127-142, 1996.